Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cytarabine, quantity: 5000 mg - injection, solution - excipient ingredients: trometamol; water for injections; macrogol 400 - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cytarabine, quantity: 1000 mg - injection, solution - excipient ingredients: water for injections; macrogol 400; trometamol - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cytarabine, quantity: 500 mg - injection, solution - excipient ingredients: water for injections; macrogol 400; trometamol - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cytarabine, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; macrogol 400; trometamol - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cytarabine, quantity: 2000 mg - injection, solution - excipient ingredients: water for injections; macrogol 400; trometamol - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cytarabine, quantity: 4000 mg - injection, solution - excipient ingredients: water for injections; macrogol 400; trometamol - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - midazolam, quantity: 5 mg - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; sodium hydroxide; water for injections - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. iv for sedation in intensive care units; intermittent administration or continuous infusion. im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - midazolam, quantity: 50 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid; sodium chloride - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. iv for sedation in intensive care units; intermittent administration or continuous infusion. im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pemetrexed disodium, quantity: 110.29 mg (equivalent: pemetrexed, qty 100 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pemetrexed disodium, quantity: 1102.9 mg (equivalent: pemetrexed, qty 1000 mg) - injection, powder for - excipient ingredients: hydrochloric acid; mannitol; sodium hydroxide - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.